Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12054657 | 0.91 | TACR1 (0.55) | PDE4BTACR1USP30 | |
| SCHEMBL2245296 | 0.91 | TACR1 (0.55) | PDE4BTACR1USP30 | |
| SCHEMBL8265031 | 0.91 | TACR1 (0.55) | PDE4BTACR1USP30 | |
| SCHEMBL2239759 | 0.91 | TACR1 (0.55) | PDE4BTACR1USP30 | |
| SCHEMBL13617897 | 0.91 | TACR1 (0.55) | PDE4BTACR1USP30 | |
| SCHEMBL7826036 | 0.90 | SLC6A2 (0.64) | PDE4BTACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8263768 | 0.89 | PDE4B (0.50) | PDE4BTACR1USP30SLC6A2SLC6A4 | |
| SCHEMBL2242242 | 0.89 | TACR1 (0.52) | PDE4BTACR1USP30 | |
| SCHEMBL10183195 | 0.89 | TACR1 (0.52) | PDE4BTACR1USP30 | |
| SCHEMBL8264132 | 0.89 | TACR1 (0.52) | PDE4BTACR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | PDE4B 457/4885TACR1 433/4885USP30 3528/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | PDE4B 543/4885TACR1 475/4885USP30 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.